10x Genomics Reports Third Quarter 2026 Financial Results

10x Genomics reported Q3 2026 revenue of $150.7 million, up 1% year over year, while gross margin rose to 75% from 67% and net loss narrowed to $19.4 million from $27.5 million. The company raised full-year 2026 revenue guidance to $625 million–$635 million from $610 million–$630 million, forecasting 4%–6% growth excluding non-recurring license and royalty revenue related to patent-litigation settlements. It began global commercial shipments of Atera and introduced Sentira, a cloud analysis platform incorporating NVIDIA accelerated computing and Anthropic's Claude.

Analysis

The useful signal is mix, not the 1% reported top-line growth: product and services revenue grew modestly while consumables expanded and instrument revenue contracted. That supports near-term recurring-use resilience, but creates a second-order dependency: consumables growth ultimately needs a healthy instrument-placement pipeline. Atera’s launch could repair that funnel, yet management’s “early demand” is not quantified, and this quarter’s spatial instrument revenue does not yet demonstrate a launch-driven acceleration. Track placements, backlog/conversion, and consumables per installed instrument on the call and in coming quarters.

The 8-point gross-margin improvement is not a clean run-rate signal: management attributes it mainly to lower inventory write-downs and mix. Expense restraint helped narrow the operating loss, but the business remains loss-making. Cash and securities reduce near-term balance-sheet pressure; the key valuation risk is that a modest guidance increase fails to support an AI/product-launch multiple if adoption takes longer than claimed. Sentira’s NVIDIA/Anthropic integrations are strategically useful distribution and workflow hooks, but no monetization or incremental revenue is established.

Near term, the call is the catalyst: investors should distinguish organic product growth from litigation-related license/royalty comparisons and demand evidence from promotional language. Over 1–3 months, placements and consumables attach rates matter more than launch enthusiasm; over 6–18 months, software adoption and repeat consumables can improve revenue quality if instrument placements recover. Contrarian read: consumables strength may be masking a fragile new-instrument cycle, while the headline margin rebound may overstate operating leverage.

Key Decisions for Investors

• Avoid chasing the headline beat before the post-close call. Treat TXG as a conditional long on pullbacks only if management provides measurable Atera placements or orders, customer conversion, and evidence that spatial consumables growth is durable.
• For an existing TXG position, keep exposure sized to execution risk; the thesis is falsified by continued instrument-revenue contraction, weakening consumables growth, or a guide/call that does not substantiate the claimed Atera demand.
• Monitor gross margin separately from underlying operating leverage. A reversal in inventory write-downs/mix benefits, or renewed expense growth without faster revenue, would undermine the apparent loss improvement.
• Do not price Sentira as a near-term earnings driver absent evidence of paid adoption, usage, or incremental customer retention. Reassess over the next 1–3 quarters as product monetization and instrument-placement data emerge.